Trovafloxacin

Drug Profile

Trovafloxacin

Alternative Names: CP-99,219; Trovafloxacin mesylate; Trovan; Turvel

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Antibacterials; Fluoroquinolones; Naphthyridines
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Bacterial infections; Genital tract infections
  • Market Withdrawal Respiratory tract infections
  • Discontinued Toxoplasmosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 20 Mar 2001 The European Commission has formally withdrawn the marketing authorisations in the European Union for trovafloxacin and alatrofloxacin
  • 20 Mar 2001 Withdrawn for Bacterial infections in European Union (PO), including Austria, Denmark, Finland, The Netherlands, Portugal and Sweden
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top